Ultragenyx Pharmaceutical (RARE) EBT Margin Growth (1y) (2017 - 2026)
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) EBT Margin Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -392.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,565.00 |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | 2,574.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,574.00 |
| Mar 31, 2026 | -2,738.00 |
| Dec 31, 2025 | 1,907.00 |
| Sep 30, 2025 | -1,676.00 |
| Jun 30, 2025 | 2,066.00 |
| Mar 31, 2025 | 4,850.00 |
| Dec 31, 2024 | 1,956.00 |
| Sep 30, 2024 | 6,666.00 |
| Jun 30, 2024 | 5,797.00 |
| Mar 31, 2024 | 626.00 |
| Dec 31, 2023 | 4,973.00 |
| Sep 30, 2023 | 10,114.00 |
| Jun 30, 2023 | 2,980.00 |
| Mar 31, 2023 | 2,719.00 |
| Dec 31, 2022 | -32.00 |
| Sep 30, 2022 | -17,411.00 |
| Jun 30, 2022 | -3,646.00 |
| Mar 31, 2022 | -5,327.00 |
| Dec 31, 2021 | -11,900.00 |
| Sep 30, 2021 | -506.00 |